Inhibition of Multiple Myeloma Using 5-Aza-2ʹ-Deoxycytidine and Bortezomib-Loaded Self-Assembling Nanoparticles
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of Multiple Myeloma Using 5-Aza-2ʹ-Deoxycytidine and Bortezomib-Loaded Self-Assembling Nanoparticles
Authors
Keywords
-
Journal
Cancer Management and Research
Volume Volume 12, Issue -, Pages 6969-6976
Publisher
Informa UK Limited
Online
2020-08-06
DOI
10.2147/cmar.s255682
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The NEDD4‐1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma
- (2019) Xi Huang et al. INTERNATIONAL JOURNAL OF CANCER
- Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
- (2018) Pilar de la Puente et al. JOURNAL OF CONTROLLED RELEASE
- Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
- (2018) Zhihong Zheng et al. Journal of Hematology & Oncology
- The multiple myelomas — current concepts in cytogenetic classification and therapy
- (2018) Shaji K. Kumar et al. Nature Reviews Clinical Oncology
- Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma
- (2018) Zhaoxin Gu et al. Acta Biomaterialia
- Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus
- (2016) Quanyin Hu et al. ADVANCED MATERIALS
- Multiple Myeloma: Diagnosis and Treatment
- (2016) S. Vincent Rajkumar et al. MAYO CLINIC PROCEEDINGS
- Dual Carfilzomib and Doxorubicin–Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma
- (2016) Jonathan D. Ashley et al. MOLECULAR CANCER THERAPEUTICS
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Uptake and Cytotoxicity of Docetaxel-Loaded Hyaluronic Acid-Grafted Oily Core Nanocapsules in MDA-MB 231 Cancer Cells
- (2014) Ibrahima Youm et al. PHARMACEUTICAL RESEARCH
- Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance and show enhanced efficacy in vivo
- (2012) T Kiziltepe et al. Blood Cancer Journal
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Genome-Wide Transcriptional Response to 5-Aza-2'-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells
- (2008) G. Heller et al. CANCER RESEARCH
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started